Clinical Trial

Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

Name: Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D — clinical trial record (NCT07399678)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

A Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants with or without Type 2 Diabetes

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2026-02-03; most recent amendment 2026-07-22.

Trial Details

NCT Number	NCT07399678
Lead Sponsor	Alveus Therapeutics, Inc.
Conditions	Overweight or Obese Adults, Overweight or Obese, Type 2 Diabetes
Enrollment	180 participants
Start Date	2025-12-29
Primary Completion	2027-04 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2026-07-23